Navigation Links
Best Practice Database Provides Benchmarks for Fixed-Dose Combination (FDC) Drug Development
Date:11/13/2008

CHAPEL HILL, N.C., Nov. 13 /PRNewswire/ -- Bio-Pharma executives are increasingly finding value in the research products and services offered by Best Practices, LLC and in particular in use of the on-demand benchmark repository known as the Best Practice Database. ( http://www.BestPracticeDatabase.com ) Although documents from the database may be accessed and downloaded individually, many commercial and operations leaders have come to find outstanding value in membership to the database which not only provides full access to all content as needed, but also includes services such as new research alerts, invitations to participate in topical new studies and ongoing advisory services to address research needs.

As biopharmaceutical companies focus on line extensions and new product development opportunities, fixed-dose combination (FDC) products have become an increasingly important segment of the market. In an effort to better understand the development strategies and issues for new FDC products, a recent study was conducted by Best Practices, LLC, with insights available in the newly published report, "Product Commercialization Excellence: Preparation and Management of Fixed-dose Combination (FDC) Drug Products." The research explored a number of critical questions, including: whether organizations seek additive or synergistic FDC drugs; why companies chose either a bioequivalence or clinical evaluation approach; and whether organizations are using external consultants and for what purposes.

Among the many benchmarks included in this study are timeframes for both bioequivalence and clinical evaluation development approaches and the number, types and frequency of tests required. Executives who are responsible for fixed-dose combination (FDC) drug development can use this data to assess the effectiveness and efficiency of their FDC drug product development programs.

To view the study abstract or complimentary summary of the full report "Product Commercialization Excellence: Preparation and Management of Fixed-dose Combination (FDC) Drug Products," click on the following link http://www3.best-in-class.com/dr337.htm .

In a benchmarking study that included such influential companies as Abbott, Bayer, Roche, Merck, Pfizer, and Sanofi-Aventis, many key topics were covered, including:
-- Bioequivalence Approach

-- Clinical Evaluation Approach

-- Lessons Learned

-- FTEs and Complexity

Among the key metrics gathered in this report are:

-- Past, Present and Future Number of FDC Drugs in Development

-- Additive vs. Synergistic Effects

-- Bioequivalence vs. Clinical Evaluation (Preferences and reasons why)

-- Starting Development Prior vs. Post Patent Expiration

-- Use of External Consultants

-- Bioequivalence - Timeframe from Conception to Final Formulation Launch

-- Clinical Evaluation - Timeframe from Conception to Final Formulation

Launch

-- Bioequivalence - Timeframe from Initiating Formulation Development to

Final Formulation Launch

-- Clinical Evaluation - Timeframe from Initiating Formulation Development

to Final Formulation Launch

-- Bioequivalence - Multiple Metrics

-- Clinical Evaluation - Multiple Metrics

-- Number of Drugs, FTEs and Timeframe to Reach First/Second Pilot PK

Study

-- Number of Drugs, FTEs and Timeframe to Reach Pivotal BE Study

-- Number of FTEs in Analytical Development

-- Timeframe from Initiating Development Work to CTM Manufacturing for

Class 1/2/4 drugs

For more information on this study or the Best Practice Database, contact Robert Naylor at rnaylor@best-in-class.com or (919) 767-9244. Interested parties may sign-up for a customized tour of the database via the following URL: http://www3.best-in-class.com/dw212.htm .

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Breast cancer prevention practices vary across Canada
2. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
3. Practice-based intervention has sustained benefits for children and families
4. Medical Malpractice at Sea
5. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
6. Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
7. Good Clinical Practice Journal Awards: Winners Announced
8. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
9. New Director of Nursing Practice Named for Nurses Association
10. OneBeacon Professional Partners to Offer Podiatrist Medical Malpractice Product
11. Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology: